Bexarotene (BioDeep_00000018110)

human metabolite blood metabolite Chemicals and Drugs

代谢物信息卡片

4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid

化学式: C24H28O2 (348.2089)
中文名称: 4-[1-(3,5,5,8,8-五甲基-5,6,7,8-四氢萘)-乙烯基]-苯甲酸, 蓓萨罗丁
谱图信息: 最多检出来源 Homo sapiens(blood) 21.11%

分子结构信息

SMILES: C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C
InChI: InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)

描述信息

Bexarotene is only found in individuals that have used or taken this drug. It is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposis sarcoma (Wikipedia). Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR_α, RXR_β, RXR_γ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XF - Retinoids for cancer treatment
C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent
D000970 - Antineoplastic Agents

同义名列表

13 个代谢物同义名

4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoate; Ligand brand OF bexarotene; Elan brand OF bexarotene; 3-Methyl-ttneb; LG69 Compound; Bexarotenum; Bexaroteno; Bexarotene; Targretin

数据库引用编号

11 个数据库交叉引用编号

ChEBI: CHEBI:50859
PubChem: 82146
HMDB: HMDB0014452
DrugBank: DB00307
ChEMBL: CHEMBL1023
Wikipedia: Bexarotene
MeSH: Bexarotene
chemspider: 74139
CAS: 153559-49-0
CAS: 166175-31-1
PMhub: MS000002518

分类词条

Retinoids

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位		关联基因列表

文献列表

Akimasa Sanagawa, Tomoaki Hayakawa, Emi Nishida, Aya Yamamoto, Kyoko Ikumi, Yukari Mori, Yuji Hotta, Kazunori Kimura, Yoko Furukawa-Hibi, Akimichi Morita. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma. The Journal of dermatology. 2023 Jul; 50(7):917-926. doi: 10.1111/1346-8138.16801. [PMID: 37041679]
Ken-Ichi Nakashima, Marina Okamura, Imari Matsumoto, Nanae Kameda, Tomoe Tsuboi, Eiji Yamaguchi, Akichika Itoh, Makoto Inoue. Regulation of adipogenesis through retinoid X receptor and/or peroxisome proliferator-activated receptor by designed lignans based on natural products in 3T3-L1 cells. Journal of natural medicines. 2023 Mar; 77(2):315-326. doi: 10.1007/s11418-022-01674-7. [PMID: 36607539]
Venkatram R Atigadda, Mahendra P Kashyap, Zhengrong Yang, Debasish Chattopadhyay, Nathalia Melo, Rajesh Sinha, Olga V Belyaeva, Chu-Fang Chou, Pi-Ling Chang, Natalia Y Kedishvili, Clinton J Grubbs, Matthew B Renfrow, Donald D Muccio, Craig A Elmets, Mohammad Athar. Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers. Journal of medicinal chemistry. 2022 11; 65(21):14409-14423. doi: 10.1021/acs.jmedchem.2c00735. [PMID: 36318154]
Huimei Fu, Lijuan Chu, He Jiao, Longyi Lin, Youping Liu, Guoliang Chen, Libo Zou, Xin Wang, Xin Di. A highly sensitive and rapid LC-MS/MS method for quantification of bexarotene in mouse plasma and brain tissue: Application to mice pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2022 Jan; 1189(?):123025. doi: 10.1016/j.jchromb.2021.123025. [PMID: 34840083]
Charles M Bowen, Lewins Walter, Ester Borras, Wenhui Wu, Zuhal Ozcan, Kyle Chang, Prashant V Bommi, Melissa W Taggart, Selvi Thirumurthi, Patrick M Lynch, Laura Reyes-Uribe, Paul A Scheet, Krishna M Sinha, Eduardo Vilar. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer prevention research (Philadelphia, Pa.). 2021 09; 14(9):851-862. doi: 10.1158/1940-6207.capr-20-0496. [PMID: 34266857]
Jessica A Moerland, Di Zhang, Lyndsey A Reich, Sarah Carapellucci, Beth Lockwood, Ana S Leal, Teresa Krieger-Burke, Bilal Aleiwi, Edmund Ellsworth, Karen T Liby. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific reports. 2020 12; 10(1):22244. doi: 10.1038/s41598-020-79260-8. [PMID: 33335263]
Shuofeng Yuan, Jasper F W Chan, Kenn K H Chik, Chris C Y Chan, Jessica O L Tsang, Ronghui Liang, Jianli Cao, Kaiming Tang, Lin-Lei Chen, Kun Wen, Jian-Piao Cai, Zi-Wei Ye, Gang Lu, Hin Chu, Dong-Yan Jin, Kwok-Yung Yuen. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacological research. 2020 09; 159(?):104960. doi: 10.1016/j.phrs.2020.104960. [PMID: 32473310]
Yasuhiro Ishihara, Hikaru Sakurai, Ami Oguro, Mayumi Tsuji, Christoph F A Vogel, Takeshi Yamazaki. Retinoid X receptor-mediated neuroprotection via CYP19 upregulation and subsequent increases in estradiol synthesis. The Journal of steroid biochemistry and molecular biology. 2019 10; 193(?):105421. doi: 10.1016/j.jsbmb.2019.105421. [PMID: 31265900]
Elham Fanaee-Danesh, Chaitanya Chakravarthi Gali, Jelena Tadic, Martina Zandl-Lang, Alexandra Carmen Kober, Vicente Roca Agujetas, Cristina de Dios, Carmen Tam-Amersdorfer, Anika Stracke, Nicole Maria Albrecher, Anil Paul Chirackal Manavalan, Marielies Reiter, Yidan Sun, Anna Colell, Frank Madeo, Ernst Malle, Ute Panzenboeck. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells. Biochimica et biophysica acta. Molecular basis of disease. 2019 09; 1865(9):2224-2245. doi: 10.1016/j.bbadis.2019.04.019. [PMID: 31055081]
Yuta Takamura, Manami Takahashi, Midori Nishii, Osamu Shibahara, Masaki Watanabe, Michiko Fujihara, Hiroki Kakuta. 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity. Bioorganic & medicinal chemistry letters. 2019 08; 29(15):1891-1894. doi: 10.1016/j.bmcl.2019.05.050. [PMID: 31160175]
Qi Zhang, Sang Beom Lee, Xu Chen, Morgan E Stevenson, Jing Pan, Donghai Xiong, Yu Zhou, Mark Steven Miller, Ronald A Lubet, Yian Wang, Shama P Mirza, Ming You. Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice. Nano letters. 2019 04; 19(4):2231-2242. doi: 10.1021/acs.nanolett.8b04309. [PMID: 30873838]
Di Zhang, Ana S Leal, Sarah Carapellucci, Pritika H Shahani, Jaskaran S Bhogal, Samir Ibrahim, San Raban, Peter W Jurutka, Pamela A Marshall, Michael B Sporn, Carl E Wagner, Karen T Liby. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention. Cancer prevention research (Philadelphia, Pa.). 2019 04; 12(4):211-224. doi: 10.1158/1940-6207.capr-18-0317. [PMID: 30760500]
Yogita Dheer, Nitin Chitranshi, Veer Gupta, Samridhi Sharma, Kanishka Pushpitha, Mojdeh Abbasi, Mehdi Mirzaei, Yuyi You, Stuart L Graham, Vivek Gupta. Retinoid x receptor modulation protects against ER stress response and rescues glaucoma phenotypes in adult mice. Experimental neurology. 2019 04; 314(?):111-125. doi: 10.1016/j.expneurol.2019.01.015. [PMID: 30703361]
Jong Bong Lee, Tae Hwan Kim, Wanshan Feng, Hyeon Gwan Choi, Atheer Zgair, Soyoung Shin, Sun Dong Yoo, Pavel Gershkovich, Beom Soo Shin. Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach. Journal of pharmaceutical sciences. 2019 02; 108(2):1047-1052. doi: 10.1016/j.xphs.2018.09.025. [PMID: 30268807]
Irene Cabello, Pedro Alia, Xavier Pintó, Cristina Muniesa, Ricardo Fernandez-de-Misa, Yerai Peñate, Mercedes Morillo, Amparo Perez-Farriols, Teresa Estrach, Rosa Izu, Fernando Gallardo, Concepción Román, Iván Cervigón, Ariadna Ortiz-Brugues, Pablo L Ortiz-Romero, Octavio Servitje. Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. JAMA dermatology. 2018 12; 154(12):1424-1431. doi: 10.1001/jamadermatol.2018.3679. [PMID: 30422238]
Frits Kamp, Holger A Scheidt, Edith Winkler, Gabriele Basset, Hannes Heinel, James M Hutchison, Loren M LaPointe, Charles R Sanders, Harald Steiner, Daniel Huster. Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its α-Helical Conformation, and Inhibits γ-Secretase Nonselectively in Liposomes. ACS chemical neuroscience. 2018 07; 9(7):1702-1713. doi: 10.1021/acschemneuro.8b00068. [PMID: 29717863]
Chu-Fang Chou, Yu-Hua Hsieh, Clinton J Grubbs, Venkatram R Atigadda, James A Mobley, Reinhard Dummer, Donald D Muccio, Isao Eto, Craig A Elmets, W Timothy Garvey, Pi-Ling Chang. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. Journal of dermatological science. 2018 Jun; 90(3):343-356. doi: 10.1016/j.jdermsci.2018.03.006. [PMID: 29599065]
Bahar Tunctan, Sefika P Kucukkavruk, Meryem Temiz-Resitoglu, Demet S Guden, Ayse N Sari, Seyhan Sahan-Firat. Bexarotene, a Selective RXRα Agonist, Reverses Hypotension Associated with Inflammation and Tissue Injury in a Rat Model of Septic Shock. Inflammation. 2018 Feb; 41(1):337-355. doi: 10.1007/s10753-017-0691-5. [PMID: 29188497]
Khalid Z Masoodi, Kurtis Eisermann, Zhenyu Yang, Javid A Dar, Laura E Pascal, Minh Nguyen, Katherine O'Malley, Erica Parrinello, Firuz G Feturi, Alex N Kenefake, Joel B Nelson, Paul A Johnston, Peter Wipf, Zhou Wang. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone. Endocrinology. 2017 10; 158(10):3152-3161. doi: 10.1210/en.2017-00408. [PMID: 28977599]
I Cabello, O Servitje, X Corbella, I Bardés, X Pintó. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clinical and experimental dermatology. 2017 Apr; 42(3):276-281. doi: 10.1111/ced.13044. [PMID: 28233333]
Pascal Heitel, Janosch Achenbach, Daniel Moser, Ewgenij Proschak, Daniel Merk. DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators. Bioorganic & medicinal chemistry letters. 2017 03; 27(5):1193-1198. doi: 10.1016/j.bmcl.2017.01.066. [PMID: 28169169]
Jong Bong Lee, Atheer Zgair, Tae Hwan Kim, Min Gi Kim, Sun Dong Yoo, Peter M Fischer, Pavel Gershkovich. Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Jan; 1040(?):73-80. doi: 10.1016/j.jchromb.2016.11.024. [PMID: 27978471]
Matthew A J Duncton, Ryan B Murray, Gary Park, Rajinder Singh. Tetrazolone as an acid bioisostere: application to marketed drugs containing a carboxylic acid. Organic & biomolecular chemistry. 2016 Oct; 14(39):9343-9347. doi: 10.1039/c6ob01646d. [PMID: 27714239]
L M Lin, F Peng, Y P Liu, D J Chai, R B Ning, C S Xu, J X Lin. Coadministration of VDR and RXR agonists synergistically alleviates atherosclerosis through inhibition of oxidative stress: An in vivo and in vitro study. Atherosclerosis. 2016 08; 251(?):273-281. doi: 10.1016/j.atherosclerosis.2016.06.005. [PMID: 27428295]
Jin-Chul Heo, Tae-Hoon Jung, Sungjin Lee, Hyun Young Kim, Gildon Choi, Myungeun Jung, Daeyoung Jung, Heung Kyoung Lee, Jung-Ok Lee, Ji-Hwan Park, Daehee Hwang, Ho Jun Seol, Heeyeong Cho. Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA. Clinical & experimental metastasis. 2016 06; 33(5):417-29. doi: 10.1007/s10585-016-9786-x. [PMID: 26957434]
Beata Nowak, Agnieszka Matuszewska, Jarosław Filipiak, Anna Nikodem, Anna Merwid-Ląd, Małgorzata Pieśniewska, Lidia Fereniec-Gołębiewska, Joanna Kwiatkowska, Adam Szeląg. The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats. Advances in medical sciences. 2016 Mar; 61(1):85-9. doi: 10.1016/j.advms.2015.09.001. [PMID: 26569440]
Jeffrey L Cummings, Kate Zhong, Jefferson W Kinney, Chelcie Heaney, Joanne Moll-Tudla, Abhinay Joshi, Michael Pontecorvo, Michael Devous, Anne Tang, James Bena. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimer's research & therapy. 2016 Jan; 8(?):4. doi: 10.1186/s13195-016-0173-2. [PMID: 26822146]
Samata Basani, Abhimanyu Garg. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. Journal of clinical lipidology. 2015 Nov; 9(6):832-836. doi: 10.1016/j.jacl.2015.08.004. [PMID: 26687705]
Amelia H Baker, James Watt, Cassie K Huang, Louis C Gerstenfeld, Jennifer J Schlezinger. Tributyltin engages multiple nuclear receptor pathways and suppresses osteogenesis in bone marrow multipotent stromal cells. Chemical research in toxicology. 2015 Jun; 28(6):1156-66. doi: 10.1021/tx500433r. [PMID: 25932594]
Makoto Inoue, Hiroki Tanabe, Ken-ichi Nakashima, Yukihiro Ishida, Hitoshi Kotani. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene. Journal of natural products. 2014 Jul; 77(7):1670-7. doi: 10.1021/np5002016. [PMID: 24959987]
Venkatram R Atigadda, Gang Xia, Anil Desphande, LeeAnn J Boerma, Susan Lobo-Ruppert, Clinton J Grubbs, Craig D Smith, Wayne J Brouillette, Donald D Muccio. Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity. Journal of medicinal chemistry. 2014 Jun; 57(12):5370-80. doi: 10.1021/jm5004792. [PMID: 24801499]
Anat Boehm-Cagan, Daniel M Michaelson. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014 May; 34(21):7293-301. doi: 10.1523/jneurosci.5198-13.2014. [PMID: 24849361]
Jacques Fantini, Coralie Di Scala, Nouara Yahi, Jean-Denis Troadec, Kevin Sadelli, Henri Chahinian, Nicolas Garmy. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides. ACS chemical neuroscience. 2014 Mar; 5(3):216-24. doi: 10.1021/cn400183w. [PMID: 24383913]
Vladimir Lerner, Chanoch Miodownik, Anatoly Gibel, Pinchas Sirota, Ilan Bush, Hadi Elliot, Ruben Benatov, Michael S Ritsner. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. The Journal of clinical psychiatry. 2013 Dec; 74(12):1224-32. doi: 10.4088/jcp.12m08160. [PMID: 24434091]
Krista McFarland, Tracy A Spalding, David Hubbard, Jian-Nong Ma, Roger Olsson, Ethan S Burstein. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS chemical neuroscience. 2013 Nov; 4(11):1430-8. doi: 10.1021/cn400100f. [PMID: 24117438]
Francesco Torino, Agnese Barnabei, Rosamaria Paragliola, Roberto Baldelli, Marialuisa Appetecchia, Salvatore Maria Corsello. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid : official journal of the American Thyroid Association. 2013 Nov; 23(11):1345-66. doi: 10.1089/thy.2013.0241. [PMID: 23750887]
Sukhmani K Padda, Laveena Chhatwani, Lisa Zhou, Charlotte D Jacobs, Arturo Lopez-Anaya, Heather A Wakelee. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anti-cancer drugs. 2013 Aug; 24(7):731-5. doi: 10.1097/cad.0b013e32836100d7. [PMID: 23552470]
Rakeshwar S Guleria, Amar B Singh, Irina T Nizamutdinova, Tatiana Souslova, Amin A Mohammad, Jonathan A Kendall, Kenneth M Baker, Jing Pan. Activation of retinoid receptor-mediated signaling ameliorates diabetes-induced cardiac dysfunction in Zucker diabetic rats. Journal of molecular and cellular cardiology. 2013 Apr; 57(?):106-18. doi: 10.1016/j.yjmcc.2013.01.017. [PMID: 23395853]
J J Scarisbrick, S Morris, R Azurdia, T Illidge, E Parry, R Graham-Brown, R Cowan, E Gallop-Evans, R Wachsmuth, M Eagle, A S Wierzbicki, H Soran, S Whittaker, E M Wain. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. The British journal of dermatology. 2013 Jan; 168(1):192-200. doi: 10.1111/bjd.12042. [PMID: 22963233]
Lian Chen, Martin Conda-Sheridan, P V Narasimha Reddy, Andrew Morrell, Eun-Jung Park, Tamara P Kondratyuk, John M Pezzuto, Richard B van Breemen, Mark Cushman. Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents. Journal of medicinal chemistry. 2012 Jun; 55(12):5965-81. doi: 10.1021/jm3006806. [PMID: 22712432]
Jordi Rodon, Charlotte D Jacobs, Quincy Chu, Eric K Rowinsky, Arturo Lopez-Anaya, Chris H Takimoto, Heather A Wakelee. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology. 2012 Mar; 69(3):825-34. doi: 10.1007/s00280-011-1770-1. [PMID: 22057853]
Heather A Wakelee, Gary Middleton, David Dunlop, Rodryg Ramlau, Natasha Leighl, Desiree Hao, Arturo Lopez-Anaya, Petr Zatloukal, Charlotte D Jacobs. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer chemotherapy and pharmacology. 2012 Mar; 69(3):815-24. doi: 10.1007/s00280-011-1771-0. [PMID: 22057854]
Heather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, Quincy Chu, Gary Middleton, David Dunlop, Rodryg Ramlau, Natasha Leighl, Eric K Rowinsky, Desiree Hao, Petr Zatloukal, Charlotte D Jacobs, Jordi Rodon. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology. 2012 Feb; 69(2):563-71. doi: 10.1007/s00280-011-1772-z. [PMID: 22057855]
Naveena B Janakiram, Altaf Mohammed, Li Qian, Chang-In Choi, Vernon E Steele, Chinthalapally V Rao. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia (New York, N.Y.). 2012 Feb; 14(2):159-68. doi: 10.1593/neo.111440. [PMID: 22431924]
Iván P Uray, Jennifer M Rodenberg, Reid P Bissonnette, Powel H Brown, Michael A Mancini. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism. Molecular pharmacology. 2012 Feb; 81(2):228-38. doi: 10.1124/mol.111.072967. [PMID: 22053058]
Hitoshi Kotani, Hiroki Tanabe, Hajime Mizukami, Sakae Amagaya, Makoto Inoue. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers. Biological & pharmaceutical bulletin. 2012; 35(1):1-9. doi: 10.1248/bpb.35.1. [PMID: 22223330]
Tomomitsu Miyagaki, Makoto Sugaya. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. Journal of dermatological science. 2011 Oct; 64(1):1-6. doi: 10.1016/j.jdermsci.2011.07.007. [PMID: 21872448]
Anne Hespel, Najet Mejdoubi-Charef, Said Yous, José Courty, Dulce Papy-Garcia, Said Charef. Interactions of bexarotene (LGD1069, Targretin) with the coagulation system. Cancer chemotherapy and pharmacology. 2011 Oct; 68(4):847-54. doi: 10.1007/s00280-010-1553-0. [PMID: 21229355]
Susan C Yanik, Amelia H Baker, Koren K Mann, Jennifer J Schlezinger. Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal cells. Toxicological sciences : an official journal of the Society of Toxicology. 2011 Aug; 122(2):476-88. doi: 10.1093/toxsci/kfr140. [PMID: 21622945]
Shabana I Khan, Jianping Zhao, Ikhlas A Khan, Larry A Walker, Asok K Dasmahapatra. Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. Reproductive biology and endocrinology : RB&E. 2011 Jun; 9(?):91. doi: 10.1186/1477-7827-9-91. [PMID: 21693041]
Jianjiang Fu, Wei Wang, Yu-Hui Liu, Hong Lu, Yongming Luo. In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells. BMC cancer. 2011 Jun; 11(?):227. doi: 10.1186/1471-2407-11-227. [PMID: 21649908]
Wen Luo, Nicholas J Schork, Keith B Marschke, Shi-Chung Ng, Thomas W Hermann, Jinkun Zhang, Jennifer M Sanders, Patricia Tooker, Nathalie Malo, Matthew A Zapala, Zofia E Dziewanowska, Andres Negro-Vilar, Martin D Meglasson. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Anticancer research. 2011 Jun; 31(6):2303-11. doi: NULL. [PMID: 21737656]
Qi Zhang, Jing Pan, Jingjie Zhang, Pengyuan Liu, Ruth Chen, Da-ren Chen, Ronald Lubet, Yian Wang, Ming You. Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice. Cancer prevention research (Philadelphia, Pa.). 2011 Feb; 4(2):270-6. doi: 10.1158/1940-6207.capr-10-0246. [PMID: 21163938]
Shiva K Ratuapli, Shishir Murarka, Karen A Miller, James C Ferraro, Haider Zafar. Epstein Barr Virus-positive large T-cell lymphoma presenting as acute appendicitis 17 years after cadaveric renal transplant: a case report. Journal of medical case reports. 2011 Jan; 5(?):5. doi: 10.1186/1752-1947-5-5. [PMID: 21226894]
Niko Escher, Robert Kob, Martin Kaatz, Christian Melle, Christina Hipler, Ferdinand von Eggeling. Confirmation of the biological significance of transthyretin as a biomarker for cutaneous T-cell lymphoma by its protein interaction partners. Molecular medicine reports. 2011 Jan; 4(1):157-61. doi: 10.3892/mmr.2010.393. [PMID: 21461579]
Agata Bielecka-Dąbrowa, Simon Hannam, Jacek Rysz, Maciej Banach. Malignancy-associated dyslipidemia. The open cardiovascular medicine journal. 2011; 5(?):35-40. doi: 10.2174/1874192401105010035. [PMID: 21660223]
Shuji Fujii, Fuminori Ohsawa, Shoya Yamada, Ryosuke Shinozaki, Ryosuke Fukai, Makoto Makishima, Shuichi Enomoto, Akihiro Tai, Hiroki Kakuta. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation. Bioorganic & medicinal chemistry letters. 2010 Sep; 20(17):5139-42. doi: 10.1016/j.bmcl.2010.07.012. [PMID: 20656484]
Hitoshi Kotani, Hiroki Tanabe, Hajime Mizukami, Makoto Makishima, Makoto Inoue. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. Journal of natural products. 2010 Aug; 73(8):1332-6. doi: 10.1021/np100120c. [PMID: 20695472]
Fanny Lalloyer, Thomas Askov Pedersen, Barbara Gross, Sophie Lestavel, Saïd Yous, Emmanuelle Vallez, Jan-Ake Gustafsson, Susanne Mandrup, Catherine Fiévet, Bart Staels, Anne Tailleux. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arteriosclerosis, thrombosis, and vascular biology. 2009 Oct; 29(10):1488-95. doi: 10.1161/atvbaha.109.189506. [PMID: 19592467]
Daria Handkiewicz-Junak, Jozef Roskosz, Kornelia Hasse-Lazar, Sylwia Szpak-Ulczok, Zbigniew Puch, Aleksandra Kukulska, Tomasz Olczyk, Andrzej Piela, Ewa Paliczka-Cieslik, Barbara Jarzab. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid research. 2009 Aug; 2(1):8. doi: 10.1186/1756-6614-2-8. [PMID: 19646277]
Nicoletta Bianchi, Cristina Zuccato, Ilaria Lampronti, Monica Borgatti, Roberto Gambari. Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of {beta}-Thalassemia and Sickle-Cell Anemia. Evidence-based complementary and alternative medicine : eCAM. 2009 Jun; 6(2):141-51. doi: 10.1093/ecam/nem139. [PMID: 18955291]
R A Abbott, S J Whittaker, S L Morris, R Russell-Jones, T Hung, S J Bashir, J J Scarisbrick. Bexarotene therapy for mycosis fungoides and Sézary syndrome. The British journal of dermatology. 2009 Jun; 160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. [PMID: 19222457]
Jitske de Vries-van der Weij, Willeke de Haan, Lihui Hu, Maarten Kuif, H Ling D W Oei, José W A van der Hoorn, Louis M Havekes, Hans M G Princen, Johannes A Romijn, Johannes W A Smit, Patrick C N Rensen. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009 May; 150(5):2368-75. doi: 10.1210/en.2008-1540. [PMID: 19147676]
Antonino Musolino, Michele Panebianco, Enrico Zendri, Marcello Santini, Sergio Di Nuzzo, Andrea Ardizzoni. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. British journal of haematology. 2009 Apr; 145(1):84-6. doi: 10.1111/j.1365-2141.2009.07596.x. [PMID: 19208096]
Ronald A Lubet, Daniel Boring, Vernon E Steele, J Michael Ruppert, M Margaret Juliana, Clinton J Grubbs. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer prevention research (Philadelphia, Pa.). 2009 Feb; 2(2):161-7. doi: 10.1158/1940-6207.capr-08-0134. [PMID: 19196723]
Masanobu Yamada, Masatomo Mori. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nature clinical practice. Endocrinology & metabolism. 2008 Dec; 4(12):683-94. doi: 10.1038/ncpendmet0995. [PMID: 18941435]
Srivalli Gopaluni, Raiza Perzova, Lynn Abbott, Ramsey Farah, Anthony Shrimpton, Robert Hutchison, Bernard J Poiesz. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. American journal of hematology. 2008 Sep; 83(9):744-6. doi: 10.1002/ajh.21231. [PMID: 18615708]
George R Blumenschein, Fadlo R Khuri, Joachim von Pawel, Ulrich Gatzemeier, Wilson H Miller, Robert M Jotte, Jacques Le Treut, Show-Li Sun, Jinkun K Zhang, Zofia E Dziewanowska, Andres Negro-Vilar. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr; 26(11):1879-85. doi: 10.1200/jco.2007.12.2689. [PMID: 18398153]
Ying Y Liu, Marcel P Stokkel, Hans A Morreau, Alberto M Pereira, Johannes A Romijn, Johannes W A Smit. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clinical endocrinology. 2008 Apr; 68(4):605-9. doi: 10.1111/j.1365-2265.2007.03096.x. [PMID: 17986279]
Thomas L Horn, Karen E O Torres, Jennifer M Naylor, Michael J Cwik, Carol J Detrisac, Izet M Kapetanovic, Ronald A Lubet, James A Crowell, David L McCormick. Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats. Toxicological sciences : an official journal of the Society of Toxicology. 2007 Oct; 99(2):612-27. doi: 10.1093/toxsci/kfm181. [PMID: 17630414]
Johannes W A Smit, Marcel P M Stokkel, Alberto M Pereira, Johannes A Romijn, Theo J Visser. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. The Journal of clinical endocrinology and metabolism. 2007 Jul; 92(7):2496-9. doi: 10.1210/jc.2006-2822. [PMID: 17440015]
Konstantin H Dragnev, W Jeffrey Petty, Sumit J Shah, Lionel D Lewis, Candice C Black, Vincent Memoli, William C Nugent, Thomas Hermann, Andres Negro-Vilar, James R Rigas, Ethan Dmitrovsky. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Mar; 13(6):1794-800. doi: 10.1158/1078-0432.ccr-06-1836. [PMID: 17363535]
Wendy M Golden, Katie B Weber, Teri L Hernandez, Steven I Sherman, Whitney W Woodmansee, Bryan R Haugen. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. The Journal of clinical endocrinology and metabolism. 2007 Jan; 92(1):124-30. doi: 10.1210/jc.2006-0696. [PMID: 17062760]
Ramaswamy Govindan, John Crowley, Lee Schwartzberg, Peter Kennedy, Charles Williams, Bradley Ekstrand, Alan Sandler, Dinah Jaunakais, Vanessa Bolejack, Richard Ghalie. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Oct; 24(30):4848-54. doi: 10.1200/jco.2006.07.7404. [PMID: 17050870]
C Assaf, M Bagot, R Dummer, M Duvic, R Gniadecki, R Knobler, A Ranki, P Schwandt, S Whittaker. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. The British journal of dermatology. 2006 Aug; 155(2):261-6. doi: 10.1111/j.1365-2133.2006.07329.x. [PMID: 16882161]
C Martin, K Bach-Ngohou, B Perrin, D Masson. [Central hypothyroidism associated with bexarotene therapy]. Annales de biologie clinique. 2006 Jul; 64(4):331-4. doi: NULL. [PMID: 16829476]
Clinton J Grubbs, Ronald A Lubet, Venkatram R Atigadda, Konstantin Christov, Anil M Deshpande, Vivek Tirmal, Gang Xia, Kirby I Bland, Isao Eto, Wayne J Brouillette, Donald D Muccio. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis. 2006 Jun; 27(6):1232-9. doi: 10.1093/carcin/bgi308. [PMID: 16344269]
S Joshi, R Guleria, J Pan, D DiPette, U S Singh. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene. 2006 Jan; 25(2):240-7. doi: 10.1038/sj.onc.1209027. [PMID: 16158052]
Thomas W Hermann, Wan-Ching Yen, Patricia Tooker, Bingqi Fan, Karen Roegner, Andrés Negro-Vilar, William W Lamph, Reid P Bissonnette. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung cancer (Amsterdam, Netherlands). 2005 Oct; 50(1):9-18. doi: 10.1016/j.lungcan.2005.05.008. [PMID: 15993980]
Donald E Tsai, Nicole A Aqui, Dan T Vogl, Roy D Bloom, Stephen J Schuster, Sunita D Nasta, Mariusz A Wasik. Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2005 Aug; 5(8):2070-3. doi: 10.1111/j.1600-6143.2005.00948.x. [PMID: 15996263]
Ronald A Lubet, Konstantin Christov, Nomeli P Nunez, Steven D Hursting, Vernon E Steele, M Margaret Juliana, Isao Eto, Clinton J Grubbs. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis. 2005 Feb; 26(2):441-8. doi: 10.1093/carcin/bgh338. [PMID: 15591091]
Pascal G P Martin, Frédéric Lasserre, Cécile Calleja, Armelle Van Es, Alain Roulet, Didier Concordet, Michela Cantiello, Romain Barnouin, Béatrice Gauthier, Thierry Pineau. Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks. Gene expression. 2005; 12(3):177-92. doi: 10.3727/000000005783992098. [PMID: 16128002]
M M A Elmazar, H Nau. Potentiation of the teratogenic effects induced by coadministration of retinoic acid or phytanic acid/phytol with synthetic retinoid receptor ligands. Archives of toxicology. 2004 Nov; 78(11):660-8. doi: 10.1007/s00204-004-0586-8. [PMID: 15558240]
Jürgen V Smit, Manon E J Franssen, Elke M G J de Jong, Julien Lambert, Diane I Roseeuw, Jozef De Weert, Richard C Yocum, Victor J Stevens, P C M van De Kerkhof. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. Journal of the American Academy of Dermatology. 2004 Aug; 51(2):249-56. doi: 10.1016/j.jaad.2002.08.001. [PMID: 15280844]
S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
N C van de Merbel, H Poelman. Experiences with monolithic LC phases in quantitative bioanalysis. Journal of pharmaceutical and biomedical analysis. 2003 Oct; 33(3):495-504. doi: 10.1016/s0731-7085(03)00297-8. [PMID: 14550867]
P H Jones, R D Burnett, I Fainaru, P Nadolny, P Walker, Z Yu, D Tang-Liu, T S Ganesan, D C Talbot, A L Harris, G J S Rustin. A phase 1 study of tazarotene in adults with advanced cancer. British journal of cancer. 2003 Sep; 89(5):808-15. doi: 10.1038/sj.bjc.6601169. [PMID: 12942109]
Steven I Sherman. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clinical lymphoma. 2003 Mar; 3(4):249-52. doi: 10.3816/clm.2003.n.006. [PMID: 12672276]
Rakhshandra Talpur, Staci Ward, Narin Apisarnthanarax, Joan Breuer-Mcham, Madeleine Duvic. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 2002 Nov; 47(5):672-84. doi: 10.1067/mjd.2002.124607. [PMID: 12399758]
N C van de Merbel, J H van Veen, G Wilkens, G Loewen. Validated liquid chromatographic method for the determination of bexarotene in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Aug; 775(2):189-95. doi: 10.1016/s1570-0232(02)00291-x. [PMID: 12113985]
Narin Apisarnthanarax, Rakshandra Talpur, Madeleine Duvic. Treatment of cutaneous T cell lymphoma: current status and future directions. American journal of clinical dermatology. 2002; 3(3):193-215. doi: 10.2165/00128071-200203030-00006. [PMID: 11978140]
S R Howell, M A Shirley, T A Grese, D A Neel, K E Wells, E H Ulm. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug metabolism and disposition: the biological fate of chemicals. 2001 Jul; 29(7):990-8. doi: NULL. [PMID: 11408365]
N Rizvi, M J Hawkins, P D Eisenberg, R C Yocum, S D Reich. Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clinical lung cancer. 2001 Feb; 2(3):210-5. doi: 10.3816/clc.2001.n.005. [PMID: 14700480]
P Heald. The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clinical lymphoma. 2000 Nov; 1 Suppl 1(?):S45-9. doi: 10.3816/clm.2000.s.009. [PMID: 11707864]
A Y Bedikian, C Plager, N Papadopoulos, J Ellerhorst, T Smith, R S Benjamin. A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma. Oncology reports. 2000 Jul; 7(4):883-6. doi: 10.3892/or.7.4.883. [PMID: 10854563]
M N Lowe, G L Plosker. Bexarotene. American journal of clinical dermatology. 2000 Jul; 1(4):245-50; discussion 251. doi: 10.2165/00128071-200001040-00006. [PMID: 11702369]
G Martin, H Poirier, N Hennuyer, D Crombie, J C Fruchart, R A Heyman, P Besnard, J Auwerx. Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. The Journal of biological chemistry. 2000 Apr; 275(17):12612-8. doi: 10.1074/jbc.275.17.12612. [PMID: 10777552]
N A Rizvi, J L Marshall, W Dahut, E Ness, J A Truglia, G Loewen, G M Gill, E H Ulm, R Geiser, D Jaunakais, M J Hawkins. A Phase I study of LGD1069 in adults with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Jul; 5(7):1658-64. doi: ". [PMID: 10430065]
S I Sherman, J Gopal, B R Haugen, A C Chiu, K Whaley, P Nowlakha, M Duvic. Central hypothyroidism associated with retinoid X receptor-selective ligands. The New England journal of medicine. 1999 Apr; 340(14):1075-9. doi: 10.1056/nejm199904083401404. [PMID: 10194237]